Journal
FUTURE ONCOLOGY
Volume 16, Issue 29, Pages 2273-2282Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0026
Keywords
brentuximab vedotin; CD30; classical Hodgkin lymphoma; stage III or IV classical Hodgkin lymphoma
Categories
Ask authors/readers for more resources
Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is US FDA approved for treatment of classic Hodgkin lymphoma (cHL) after progression or relapse of at least two prior lines of chemotherapy or autologous stem cell transplantation, as consolidation therapy after autologous stem cell transplantation for high-risk patients and as a front-line therapy for previously untreated, advanced-stage cHL in combination with chemotherapy. BV is a well-tolerated treatment in previously heavily pretreated relapsed/refractory cHL and in treatment-naive patients. BV use, in combination with other antineoplastic agents for cHL, is under investigation in multiple prospective clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available